Type 2 Diabetes

ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes

ACP responds to criticism from the ADA, the Endocrine Society, the AACE, and the AADE of guidance that clinicians should aim to achieve an HbA1c ...

Case for Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes

An increasing number of studies support the use of continuous glucose monitoring in adult patients with T2D, and the observed benefits are likely to extend ...

Ask the Experts: Dr Goyal on SGLT2 Inhibitors

Dr Goyal from NYU Langone Health in New York City talks about SGLT2 inhibitors in the treatment of type 2 diabetes.

Addressing Psychological Insulin Resistance in Patients With Diabetes

Learn about strategies to reduce a patient's reluctance to initiate insulin therapy, a phenomenon called psychological insulin resistance.

Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging

Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.

In-Hospital Tramadol Use Increases Hypoglycemia Risk in T1D, T2D

Results indicate that blood glucose monitoring should be conducted in hospitalized patients with diabetes.

Type 2 Diabetes and Antidepressant Drug Use: Is There a Causal Link?

Updated meta-analysis confirms the association between antidepressant drug (AD) use and incident diabetes. Future studies should be aimed at evaluating the effect of single AD ...

Video

Latest Headlines

Semaglutide vs Dulaglutide for HbA1c, Body Weight Reduction in T2D

Semaglutide vs Dulaglutide for HbA1c, Body Weight Reduction in T2D

Semaglutide was associated with HbA1c and body weight reductions compared with patients taking dulaglutide.

High-Intensity Statins Do Not Worsen Glucose Homeostasis in Type 2 Diabetes

High-Intensity Statins Do Not Worsen Glucose Homeostasis in Type 2 Diabetes

The effect of high-intensity statins compared with low-intensity statins on glycemic control was examined.

Exenatide Shows Efficacy in Improving Renal Outcomes in T2D

Exenatide Shows Efficacy in Improving Renal Outcomes in T2D

Investigators examined the effect of exenatide on estimated glomerular filtration rate, new macroalbuminuria, and 2 renal composites.

Empagliflozin Reduces Risk for Nephropathy Regardless of Blood Pressure, LDL Cholesterol, HbA1c

Empagliflozin Reduces Risk for Nephropathy Regardless of Blood Pressure, LDL Cholesterol, HbA1c

Investigators examined renal outcomes when controlling cardiovascular risk factors, such as blood pressure, LDL-C, and HbA1c.

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

Investigators examined the prevalence of chronic kidney disease in adults with type 1 diabetes compared with type 2 diabetes.

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

Information-Motivation-Behavioral Skills Model Identifies Barriers to Diabetes Medication Adherence

Information-Motivation-Behavioral Skills Model Identifies Barriers to Diabetes Medication Adherence

Investigators used the Information-Motivation-Behavioral skills model of adherence to examine associations between patient characteristics and barriers to adherence to treatment for type 2 diabetes.

Increased Risk for Parkinson Disease in Individuals With Type 2 Diabetes

Increased Risk for Parkinson Disease in Individuals With Type 2 Diabetes

A retrospective cohort study was conducted to determine whether individuals with preexisting type 2 diabetes are at increased risk of developing Parkinson disease.

Associated Outcomes for Metformin-Based Diabetes Treatment After Kidney Transplant

Associated Outcomes for Metformin-Based Diabetes Treatment After Kidney Transplant

Outcomes associated with metformin use for diabetes in patients requiring kidney transplantation were assessed in an observational study linking Scientific Registry of Transplant Recipient data with US pharmacy claims data.

Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes

Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes

Investigators examined the safety and efficacy of empagliflozin 10mg and linagliptin 5 mg in patients uncontrolled on linagliptin.

Sign Up for Free e-Newsletters



CME Focus